Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 25, 2026Scientific ReportsOpen Access

Heterologous saRNA prime – multivalent protein boost strategy induces broad and durable immunity against SARS-CoV-2 and MERS-CoV

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDominik RennJMJustine S. McPartlanSBSrinivas Banala

Discussion

Loading...

Member takes

Overview

Preclinical trials demonstrate enhanced immunity against coronaviruses in animal models, suggesting a new vaccine approach.

Key Points

  • The research aims to develop a vaccine strategy that provides broad immunity against multiple coronaviruses.
  • Utilized a heterologous prime-boost vaccination strategy.
  • Combined a modified dendrimer nanoparticle-encapsulated saRNA prime with an alum-adjuvanted multivalent protein booster.
  • Targeted receptor-binding domains from SARS-CoV-2 and MERS-CoV.
  • Conducted preclinical trials in mouse and hamster models.
  • Elicited robust antibody responses with greater magnitude and durability compared to traditional vaccination methods.
  • Broad antiviral response observed against both SARS-CoV-2 and MERS-CoV.
  • Inclusion of MERS-CoV RBD did not compromise immunity against SARS-CoV-2.

Cite This Study

Renn et al. (2026) studied this question.

synapsesocial.com/papers/69c37b62b34aaaeb1a67dc4fhttps://doi.org/10.1038/s41598-026-44645-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of the impact of the COVID-19 pandemic on health service utilization in China: A study using auto-regressive integrated moving average model2023 · 13 citations
  2. 2Emergence of Bat-Related Betacoronaviruses: Hazard and Risks2021 · 74 citations
  3. 3The Importance of CXCL1 in Physiology and Noncancerous Diseases of Bone, Bone Marrow, Muscle and the Nervous System2022 · 90 citations
  4. 4Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination2021 · 740 citations
  5. 5The SARS-CoV-2 antibody-dependent enhancement façade2024 · 14 citations